Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP9 | P14780 | 8/20 | 0.46 |
| ▸ | MMP2 | P08253 | 7/20 | 0.46 |
| ▸ | MMP12 | P39900 | 7/20 | 0.46 |
| ▸ | MMP8 | P22894 | 5/20 | 0.46 |
| ▸ | MMP14 | P50281 | 4/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | MMP13 | P45452 | 5/20 | 0.44 |
| ▸ | MMP3 | P08254 | 1/20 | 0.44 |
| ▸ | CTSL | P07711 | 1/20 | 0.43 |
| ▸ | CTSS | P25774 | 1/20 | 0.43 |
| ▸ | CTSK | P43235 | 1/20 | 0.43 |
| ▸ | MMP1 | P03956 | 3/20 | 0.42 |
| ▸ | MMP7 | P09237 | 3/20 | 0.42 |
| ▸ | ACE | P12821 | 2/20 | 0.42 |
| ▸ | METAP2 | P50579 | 1/20 | 0.41 |
| ▸ | PLAU | P00749 | 2/20 | 0.41 |
| ▸ | HPN | P05981 | 2/20 | 0.41 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5191279 | 0.81 | MMP9 (0.64) | MMP9MMP2MMP12MMP8MMP14 | |
| SCHEMBL599969 | 0.81 | MMP9 (0.64) | MMP9MMP2MMP12MMP8MMP14 | |
| SCHEMBL8147112 | 0.77 | SMN1; SMN2 (0.52) | MMP9MMP2MMP12MMP8MMP14 | |
| SCHEMBL1403263 | 0.77 | SMN1; SMN2 (0.52) | MMP9MMP2MMP12MMP8MMP14 | |
| SCHEMBL7932963 | 0.76 | SMN1; SMN2 (0.51) | MMP9MMP2MMP12MMP8MMP14 | |
| SCHEMBL5524025 | 0.75 | LMNA (0.52) | CTSLCTSSCTSK | |
| SCHEMBL6122905 | 0.74 | BMP1 (0.45) | MMP9MMP2MMP12MMP8MMP14 | |
| SCHEMBL31014184 | 0.74 | SMN1; SMN2 (0.55) | MMP9MMP2MMP12MMP8MMP14 | |
| SCHEMBL6061725 | 0.72 | CTSL (0.51) | CTSLCTSSCTSK | |
| SCHEMBL5875648 | 0.72 | SMN1; SMN2 (0.64) | MMP9MMP2MMP12MMP8MMP14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1161415-B1 | N-CYANOMETHYLAMIDES AS PROTEASE INHIBITORS | AXYS PHARM INC (US) | 2005-07-13 | — | — | EP | disclosed |
| US-6593327-B2 | N-cyanomethyl amides which are cysteine protease inhibitors; treating osteoporosis; mixtures with bisphosphonates | AXYS PHARMACEUTICALS, INC. | 2003-07-15 | — | — | US | disclosed |
| US-20030119788-A1 | Novel compounds and compositions as protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2003-06-26 | — | — | US | disclosed |
| US-6476026-B1 | Compounds and compositions as protease inhibitors | AXYS PHARMACEUTICALS, INC. | 2002-11-05 | — | — | US | disclosed |
| US-20020086996-A1 | Novel compounds and compositions as protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2002-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020086996-A1 | Novel compounds and compositions as protease inhibitors | CTRL, SERPINB1, CPN1 | MMP9 95/4885MMP2 75/4885MMP12 225/4885 |
| US-20030119788-A1 | Novel compounds and compositions as protease inhibitors | CTRL, SERPINB1, CPN1 | MMP9 95/4885MMP2 75/4885MMP12 225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.